JIANG ZHONG PHARMACEUTICAL CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.07 CNY | +0.89% |
|
-0.04% | +24.86% |
| Apr. 26 | Jiang Zhong Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 25 | Jiang Zhong Pharmaceutical Co.,Ltd Proposes Cash Dividend | CI |
| Sales 2024 * | 4.97B 686M | Sales 2025 * | 5.58B 771M | Capitalization | 16.24B 2.24B |
|---|---|---|---|---|---|
| Net income 2024 * | 826M 114M | Net income 2025 * | 933M 129M | EV / Sales 2024 * | 3.01 x |
| Net cash position 2024 * | 1.27B 176M | Net cash position 2025 * | 1.08B 148M | EV / Sales 2025 * | 2.72 x |
| P/E ratio 2024 * |
19.9
x | P/E ratio 2025 * |
17.6
x | Employees | - |
| Yield 2024 * |
5.27% | Yield 2025 * |
5.64% | Free-Float | 51.07% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.89% | ||
| 1 week | -0.04% | ||
| 1 month | -2.21% | ||
| 3 months | +11.98% | ||
| 6 months | +17.22% | ||
| Current year | +24.86% |
1 week
25.66
26.72
1 month
25.6628.31
Current year
19.1128.58
1 year
17.5028.58
3 years
10.8428.58
5 years
9.3328.58
10 years
7.2728.58
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Bin Xiao
CEO | Chief Executive Officer | 44 | 21-01-11 |
Xiao Jun Li
DFI | Director of Finance/CFO | 43 | 20-03-18 |
Yang Tang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Quan Liu
CHM | Chairman | 53 | 09-09-17 |
Na Tang
BRD | Director/Board Member | 48 | 22-11-16 |
Rong Deng
BRD | Director/Board Member | 46 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.25% | 4 M€ | -2.96% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 26.07 | +0.89% | 4,770,645 |
| 24-05-30 | 25.84 | -1.52% | 5,175,199 |
| 24-05-29 | 26.24 | -0.91% | 5,637,993 |
| 24-05-28 | 26.48 | -0.38% | 5,073,446 |
| 24-05-27 | 26.58 | +1.92% | 6,669,319 |
End-of-day quote Shanghai S.E., May 30, 2024
More quotes
Jiang Zhong Pharmaceutical Co Ltd is a China-based company mainly engaged in the pharmaceutical manufacturing industry. The Company's products are classified into over-the-counter drugs, prescription drugs, big health products and others, covering the fields of spleen and stomach, intestines, throat, tonic, rehabilitation nutrition, high-end tonic, cardiovascular and cerebrovascular, gynecology, urinary system and others OTC products include Jianweixiaoshi Tablets, Lactobacillus Tablets, Compound Coral Grass Tablets, and Bifidobacterium Triple Live Enteric Capsules. Health products mainly include peptides and protein powder products. Prescription drug products include Chinese medicine products such as Bazhen Yimu Capsules, Shenbao Capsules, Paishi Granules, Huangqi Shengmai Yin, Zhenju Jiangya Tablets, Shuangju Granules, Zhikang Tablets, Shuxiong Granules and others
Sector
Pharmaceuticals
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
26.07
CNY
Average target price
31.12
CNY
Spread / Average Target
+19.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +24.86% | 2.24B | |
| +40.73% | 739B | |
| +31.57% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.25% | 240B | |
| +9.53% | 210B | |
| -5.11% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 600750 Stock
